Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany

被引：0
|
作者：
Campone, M. [1 ]
Frenel, J-S. [1 ]
Kiver, V. I. I. [2 ,3 ,4 ]
Woeckel, A. [5 ]
Kerscher, A. G. [6 ]
Krebs, M. [6 ]
Leal, C. S. [7 ]
Saglimbene, V. M. [8 ]
Trankov, N. [9 ]
Sadetsky, N. [10 ]
Sjekloca, N. [11 ]
Libert, O. [12 ]
Kaushik, A. G. [13 ]
Bocquet, F. [14 ]
机构：
[1] ICO Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, St Herblain, France
[2] Charite Univ Med Berlin, Breast Ctr, Dept Gynecol, Berlin, Germany
[3] Free Univ Berlin, Berlin, Germany
[4] Humboldt Univ, Berlin, Germany
[5] Univ Hosp Wurzburg, Dept Obstet & Gynecol, Wurzburg, Germany
[6] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[7] IQVIA, Epidemiol & Database Studies, Porto Salvo, Portugal
[8] IQVIA Italy, EMEA Real World Methods & Evidence Generat, Milan, Italy
[9] IQVIA, EMEA Real World Methods & Evidence Generat, Sofia, Bulgaria
[10] Gilead Sci Inc, RWE Oncol, Foster City, CA USA
[11] Gilead Sci Europe Ltd, Global Med Affairs, Stockley Pk, England
[12] Gilead Sci SAS, Med Affairs, Boulogne, France
[13] Gilead Sci Inc, Hlth Econ Outcomes Res, Foster City, CA USA
[14] Inst Cancerol Ouest, Data Factory & Analyt, St Herblain, France
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.322
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
374P
引用
收藏
页码：S375 / S376
页数：2
相关论文
共 50 条
  • [1] Impact of comorbidities on real-world (rw) clinical outcomes of patients (pts) with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib and enrolled in POLARIS
    Tripathy, D.
    Blum, J. L.
    Karuturi, M. S.
    McCune, S.
    Kurian, S.
    Moezi, M. M.
    Anderson, D. M.
    Wang, Y.
    Montelongo, M. Z.
    Zhang, Z.
    Gauthier, E.
    Rocque, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S332 - S332
  • [2] Real-world treatment durations without chemotherapy (CT) for hormone-receptor-positive (HR plus )/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC)
    Swallow, Elyse
    Wang, Jenny
    Thomason, Darren
    Tan, Ruo-Ding
    Kageleiry, Andrew
    Signorovitch, James
    CANCER RESEARCH, 2015, 75
  • [3] "Real world" characteristics, treatment patterns and outcomes of patients with hormone receptor positive (HR plus ), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC)
    Twelves, C.
    Cheeseman, S.
    Thompson, M.
    Riaz, M.
    Perren, T.
    Ahat-Donker, N.
    Sopwith, W.
    Myland, M.
    Lee, A.
    Turner, S.
    Hall, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
    Engel-Nitz, Nicole M.
    Johnson, Mary G.
    Johnson, Michael P.
    Cha-Silva, Ashley S.
    Kurosky, Samantha K.
    Liu, Xianchen
    PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 1049 - 1062
  • [5] Clinical characteristics, treatment patterns, and survival outcomes in women with early triple-negative (TN) or hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) breast cancer (BC) in the real-world (RW) setting
    Gogate, Anagha
    Crosbie, Amanda
    Le, Trong Kim
    Zhang, Ying
    Das, Rolee
    Davis, Catherine
    CANCER RESEARCH, 2022, 82 (04)
  • [6] Laboratory monitoring in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer treated with palbociclib in a real-world setting: Results from POLARIS
    Rocque, Gabrielle B.
    Blum, Joanne L.
    Specht, Jennifer M.
    Dul, Carrie
    Corso, Steven
    Cuevas, Daniel
    Gauthier, Eric
    Montelongo, Monica Z.
    Zhang, Zhe
    Wang, Yao
    Tripathy, Debu
    CANCER RESEARCH, 2023, 83 (05)
  • [7] Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune checkpoint inhibitors (ICI)
    Chumsri, S.
    Sammons, S.
    Alder, L.
    Sokol, E.
    Danziger, N. A.
    Raskina, K.
    Schrock, A. B.
    Venstrom, J.
    Snow, T.
    Castellanos, E.
    Ochuonyo, E.
    Snider, J.
    Mcgregor, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S462 - S463
  • [8] Characterization of neutropenia in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS
    Tripathy, Debu
    Blum, Joanne L.
    Sleckman, Bethany
    Patel, Kamal
    Nakhoul, Ibrahim
    Gauthier, Eric
    Montelongo, Monica Z.
    Zhang, Zhe
    Wang, Yao
    Rocque, Gabrielle B.
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC)
    Lloyd, Maxwell Roger
    Ali, Azka
    Weipert, Caroline M.
    Solomon, Sheila R.
    Saha, Jayati
    Lipsyc-Sharf, Marla
    Hamilton, Erika P.
    Kalinsky, Kevin
    Bardia, Aditya
    Zhang, Nicole
    Wander, Seth Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Impact of comorbidities on real-world patient-reported outcomes of patients (pts) with hormone receptor-positive human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) enrolled in the POLARIS trial
    Blum, J. L.
    Rocque, G.
    Ji, Y.
    Pluard, T.
    Migas, J.
    Lakhanpal, S.
    Jepsen, E.
    Gauthier, E.
    Wang, Y.
    Montelongo, M. Z.
    Cappelleri, J.
    Chen, C.
    Karuturi, M. S.
    Tripathy, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S375 - S375
12345